相关实验视频
Updated: May 4, 2026
08:23
LAD-Ligation: A Murine Model of Myocardial Infarction
Published on: October 14, 2009
44.5K
缓解小鼠急性和慢性Coxsackievirus B3诱导心肌炎与人类右心房附属体衍生的肌层细胞
Muhammad El-Shafeey1,2,3, Kathleen Pappritz1,2, Isabel Voss1,2
1Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany.
Stem cells translational medicine
|March 20, 2025
概括
来自右心房附属体 (RAA-CardAPs) 的人类心脏细胞显示出治疗病毒性心肌炎的前景. 这些细胞在急性和慢性实验模型中减少心脏纤维化和炎症.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 人体内心肌活检 (EMB) 衍生的心脏附着增殖细胞 (CardAPs) 显示了病毒诱导心肌炎的治疗潜力.
- 由于EMB的细胞产量有限,因此需要替代源来实现更广泛的治疗应用.
研究的目的:
- 评估RAA-CardAPs在实验性Coxsackievirus B3 (CVB3) 诱导的心肌炎中的心脏保护和免疫调节作用.
- 评估RAA-CardAPs在急性和慢性心肌炎模型中的疗效.
主要方法:
- 在小鼠体内内CVB3感染,随后静脉注射RAA-CardAPs,EMB-CardAPs或PBS.
- 在感染后的特定时间点评估心脏功能,纤维化和左心室和中的炎症标志物.
- 将RAA-CardAP与EMB-CardAP作为急性模型中的参考数据进行比较.
主要成果:
- 在急性CVB3心肌炎中,RAA-CardAPs治疗减少了心脏纤维化和改善了心脏功能.
- 观察到免疫调节效应,包括急性模型中降低化学激素表达 (CCL2,CCL7) 和减少炎症细胞标志物.
- 在慢性模型中,RAA-CardAPs减轻了心脏纤维化,降低了心肌炎的严重程度,改善了左心室功能.
结论:
- 在实验性病毒性心肌炎中,RAA-CardAPs显示出显著的心脏保护和免疫调节潜力.
- RAA-CardAPs代表了一种可行的基于细胞的治疗策略,用于治疗急性和慢性CVB3诱导的心肌炎.
- 对RAA-CardAPs的异构应用和现成使用对于心肌炎治疗是可行的.
相关概念视频
01:21Myocarditis I: Introduction
645
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
645
01:27Myocarditis II: Clinical Features and Diagnostic Tests
493
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
493
01:14Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
01:17Pericarditis III: Medical Management
586
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
586
01:23Rheumatic Heart Disease I: Introduction
1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805